Cangrelor
Active ingredient: Cangrelor
In short: Cangrelor for injection is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are n
What is Cangrelor used for?
Cangrelor for injection is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor .
Cangrelor dosage
The recommended dosage of Cangrelor for injection is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer.
To maintain platelet inhibition after discontinuation of Cangrelor for injection infusion, administer an oral P2Y12 platelet inhibitor, as described below:
Ticagrelor: 180 mg at any time during Cangrelor for injection infusion or immediately after discontinuation .
Prasugrel: 60 mg immediately after discontinuation of Cangrelor for injection .
Clopidogrel: 600 mg immediately after discontinuation of Cangrelor for injection .
Cangrelor for injection is intended for IV administration, after reconstitution and dilution.
Preparation
Reconstitute the vial prior to dilution in a bag. For each 50 mg/vial, reconstitute by adding 5 mL of Sterile Water for Injection. Swirl gently until all material is dissolved. Avoid vigorous mixing. Allow any foam to settle. Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colorless to pale yellow solution. Parenteral drug products should be inspected visually for particulate matter after reconstitution.
Before administration, each reconstituted vial must be diluted further with Normal Saline (Sodium Chloride Injection 0.9% USP) or 5% Dextrose Injection USP.
Withdraw the contents from one reconstituted vial and add to one 250 mL saline bag. Mix the bag thoroughly. This dilution will result in a concentration of 200 mcg/mL and should be sufficient for at least 2 hours of dosing. Patients 100 kg and over will require a minimum of 2 bags.
Reconstituted Cangrelor for injection should be diluted immediately. Diluted Cangrelor for injection is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in Normal Saline at Room Temperature. Discard any unused portion of reconstituted solution remaining in the vial.
Administration
Administer Cangrelor for injection via a dedicated IV line.Administer the bolus volume rapidly (<1 minute), from the diluted bag via manual IV push or pump. Ensure the bolus is completely administered before the start of PCI. Start the infusion immediately after administration of the bolus .
Warnings & precautions
Do not take this medicine if: Cangrelor is contraindicated in patients with significant active bleeding .
Cangrelor is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product .
Drugs that inhibit platelet P2Y12 function, including cangrelor, increase the risk of bleeding.In CHAMPION PHOENIX bleeding events of all severities were more common with cangrelor than with clopidogrel . Bleeding complications with cangrelor were consistent across a variety of clinically important subgroups .Once cangrelor is discontinued, there is no antiplatelet effect after an hour .
Cangrelor side effects
The following adverse reactions are also discussed elsewhere in the labeling:• Bleeding
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The safety of cangrelor has been evaluated in 13,301 subjects in controlled trials, in whom, 5,529 were in the CHAMPION PHOENIX trial.
Bleeding
There was a greater incidence of bleeding with cangrelor than with clopidogrel. No baseline demographic factor altered the relative risk of bleeding with cangrelor .
Table 1: Major Bleeding Results in the CHAMPION PHOENIX Study (Non-CABG related Bleeding)a
CHAMPION PHOENIX | Cangrelor (N=5529) | Clopidogrel (N=5527)
Any GUSTO bleeding, n (%) | 857 (15.5) | 602 (10.9)
Severe/life-threateningb | 11 (0.2) | 6 (0.1)
Moderate c | 21 (0.4) | 14 (0.3)
Mild d | 825 (14.9) | 582 (10.5)
Any TIMI bleeding, n (%) | 45 (0.8) | 17 (0.3)
Majore | 12 (0.2) | 6 (0.1)
Minorf | 33 (0.6) | 11 (0.2)
Abbreviations: GUSTO: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; TIMI: Thrombolysis in Myocardial Infarction
a Safety population is all randomized subjects who received at least one dose of study drug
b intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment
c requiring blood transfusion but not resulting in …
Drug interactions
Clopidogrel or prasugrel administered during cangrelor infusion will have no antiplatelet effect until the next dose is administered. Therefore, administer Clopidogrel or prasugrel after cangrelor infusion is discontinued .
About this medicine
Cangrelor for injection is a direct-acting P2Y12 platelet receptor inhibitor that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation. The chemical structure is similar to adenosine triphosphate (ATP). The chemical name of Cangrelor for injection is tetrasodium salt of N6-[2-(methylthio)ethyl]-2-[(3,3,3,trifluoropropyl)-5’-adenylic acid, monanhydride with (dichloromethylene) bisphosphonic acid. The empirical formula of Cangrelor tetrasodium is C17H21N5Cl2F3Na4O12P3S2 and the molecular weight is 864.3 g/mol. The chemical structure is represented below:
Cangrelor for Injection is a sterile white to off-white lyophilized powder for IV infusion. In addition to the active ingredient, Cangrelor, each single dose vial contains mannitol (158 mg), sorbitol (52 mg), and sodium hydroxide to adjust the pH.
How it works: Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c86264c2-ef49-4524-b6af-edb7a6279faa. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol